A Prognostic Risk Model for Breast Cancer Integrating Migrasome and Tumor Microenvironment Features to Predict Immunological Characteristics
Cancer Research and Treatment · 15.07.2026
DOI: 10.4143/crt.2025.1417 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Research and Treatment, online erschienen am 15.07.2026. Verfasst von Jingbo Du und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes o….
Abstract (Originalsprache)
Purpose
Breast cancer (BRCA) is a heterogeneous disease with a complex etiology. The prognostic value of genes related to migrasomes and the tumor microenvironment (MTMERGs) in BRCA is unclear. Materials and Methods: A prognostic risk model was constructed using six core signature genes identified from MTMERGs via differential expression analysis and Cox regression. Its reliability was validated in an independent cohort using Kaplan-Meier and time-dependent ROC curves. A nomogram was developed and assessed via Decision Curve Analysis (DCA). Biological functions and immune infiltration were evaluated with GSEA, CIBERSORT, and ssGSEA. Immunotherapy sensitivity was predicted using TIDE/IPS scores and the IMvigor210 cohort. Tumor Mutation Burden (TMB) analysis and the pRRophetic algorithm were used for further clinical correlation and drug sensitivity prediction.
Results
The six-MTMERG model effectively stratified patients into high- and low-risk groups with distinct survival outcomes. The high-risk group was associated with a predicted immunosuppressive microenvironment (estimated enrichment of M0/M2 macrophages), higher TMB, and poorer prognosis. In contrast, the low-risk group was estimated to possess an immunologically active profile and showed a better predicted response to immune checkpoint inhibitors. Predicted differential sensitivities to conventional chemotherapy were also computationally evaluated between the subgroups.
Conclusion
We developed a computationally derived and externally validated prognostic model for BRCA based on migrasome and tumor microenvironment features. It successfully stratifies patients into groups with divergent clinical outcomes, immune profiles, and therapeutic responses, providing insights into BRCA heterogeneity and prognosis. Further prospective and experimental validation is warranted before clinical application.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General Surgery, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
- Department of General Surgery, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China. zlin265@163.com.
Zitieren
APA
Du, J., & Zhu, L. (2026). A Prognostic Risk Model for Breast Cancer Integrating Migrasome and Tumor Microenvironment Features to Predict Immunological Characteristics. Cancer Research and Treatment. https://doi.org/10.4143/crt.2025.1417
Vancouver
Du J, Zhu L. A Prognostic Risk Model for Breast Cancer Integrating Migrasome and Tumor Microenvironment Features to Predict Immunological Characteristics. Cancer Research and Treatment. 2026. doi:10.4143/crt.2025.1417
BibTeX
@article{Du2026,
author = {Du, Jingbo and Zhu, Lin},
title = {A Prognostic Risk Model for Breast Cancer Integrating Migrasome and Tumor Microenvironment Features to Predict Immunological Characteristics},
journal = {Cancer Research and Treatment},
year = {2026},
doi = {10.4143/crt.2025.1417}
}
EUVIMED